American Well (NYSE:AMWL) versus Evaxion A/S (NASDAQ:EVAX) Critical Survey

American Well (NYSE:AMWL) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings and Valuation

This table compares American Well and Evaxion A/S”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
American Well	$249.32 million	0.60	-$95.70 million	($5.42)	-1.66
Evaxion A/S	$7.53 million	3.68	-$7.71 million	($1.47)	-2.26

Evaxion A/S has lower revenue, but higher earnings than American Well. Evaxion A/S is trading at a lower price-to-earnings ratio than American Well, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares American Well and Evaxion A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
American Well	-37.02%	-32.11%	-24.12%
Evaxion A/S	N/A	-73.56%	-37.45%

Volatility & Risk

American Well has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for American Well and Evaxion A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
American Well	1	3	1	0	2.00
Evaxion A/S	1	0	5	0	2.67

American Well currently has a consensus target price of $7.20, suggesting a potential downside of 20.18%. Evaxion A/S has a consensus target price of $11.00, suggesting a potential upside of 230.83%. Given Evaxion A/S’s stronger consensus rating and higher probable upside, analysts plainly believe Evaxion A/S is more favorable than American Well.

Insider and Institutional Ownership

56.1% of American Well shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 12.8% of American Well shares are owned by insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Evaxion A/S beats American Well on 8 of the 14 factors compared between the two stocks.

About American Well

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members. It provides Carepoint devices comprising carts, peripherals, tablets, and TVs, which serve as digital access points in clinical settings. In addition, the company offers Amwell Medical Group network services consisting of primary and urgent care, behavioral health therapy, acute psychiatry, lactation counseling, and nutrition services. Further, it provides professional services to facilitate implementation, workflow design, systems integration, and service expansion for its products, as well as patient and provider engagement services. The company sells its products through field sales professionals, channel partners, and value-added resellers. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.